If you’re eyeing Novo Nordisk stock right now, you’re not alone. Investors have been left scratching their heads as to what comes next, after several twists in the company’s share price. In the past week, shares in Novo Nordisk slipped by 0.5%, following a stronger run over the last month with a climb of 6.9%….
00:02 Speaker A Now, time for some of today’s trending tickers. We are watching Synopsys, Novo Nordisk and Chewy. 00:09 Speaker A First up is Synopsys, the chip design software maker plunging after warning that US export restrictions are contributing to a slowdown in China. That’s the largest market for semiconductors. 00:23 Speaker A The…
Danish pharmaceutical company Novo Nordisk, maker of weight-loss drug Wegovy, said Wednesday it is cutting 9,000 jobs, or 11% of its workforce, amid increased competition for obesity medications. The company said it will cut about 5,000 jobs in Denmark, although it didn’t disclose where the remaining 4,000 reductions will be located. Novo Nordisk also makes…
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 13.9% in the afternoon session after its oral weight-loss drug trial results disappointed investors, overshadowing an otherwise strong quarterly earnings report and guidance increase. The pharmaceutical company announced late-stage trial data for its oral weight-loss pill, orforglipron, which showed an average weight loss of 12.4%. This…
Despite a steep 65% drop from its all-time high of 145.99 a share in the prior 12 months, Novo Nordisk remains one of the most operationally sound businesses on the planet. As an investor, you are getting exposure to the booming GLP-1 drug market and the stable, cash-rich insulin and diabetes care business, serving a…
COPENHAGEN, DENMARK (Reuters) -Shares in Wegovy maker Novo Nordisk (NVO, NOVO-B.CO)continued to slide on Wednesday as analysts warned of persistent competition from copycat drugs in the U.S., a day after a profit warning and the naming of a new CEO prompted investors to wipe $70 billion off the drugmaker’s value. Novo Nordisk on Tuesday slashed…
Hims & Hers Health has experienced a tumultuous quarter, marked by Novo Nordisk’s termination of their collaboration after allegations of unsafe practices, resulting in a 35% drop in the company’s share price. This partnership termination, alongside a class action lawsuit alleging misleading statements about safety and operational risks, contributed to heightened market volatility. Despite a…
© 2025 Bloomberg Finance LP Hims & Hers cofounder and CEO Andrew Dudum dropped out of Forbes’ billionaire ranks on Monday – less than two months after joining the three-comma-club, in May. Dudum, 36, lost more than $400 million in wealth in a single trading day, after shares of his telehealth firm, known for its…
Novo Nordisk is pulling the plug on its partnership with Hims & Hers Health over claims that the telehealth company sold fake versions of the pharmaceutical firm’s weight-loss drug, Wegovy. The Danish drugmaker said Monday that Wegovy will no longer be available on Hims & Hers and that it is ending the collaboration because the San…